STERIS delivered a quarter that met Wall Street’s expectations, driven by strong underlying demand in its Healthcare and Life Sciences segments, as well as a notable contribution from tariff refunds. Management attributed revenue growth to higher procedure volumes, continued share gains in consumables, and service outperformance, with CEO Dan Carestio highlighting the “strength of our portfolio and commercial teams” in navigating a complex operating environment. Additionally, margin expansion was supported by $20 million in tariff refunds, though underlying margins faced some offset from inflation and increased R&D investment.
Is now the time to buy STE? Find out in our full research report (it’s free for active Edge members).
STERIS (STE) Q3 CY2026 highlights:
- Revenue $1.59 billion vs S&P analysts’ estimates of $1.56 billion (8.8% year-on-year growth, 1.7% beat)
- Adjusted EPS $2.94 vs S&P analysts’ estimates of $2.68 (9.8% beat)
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $11.45 at the midpoint, a 2.2% increase
- Operating margin 18.5%, in line with the same quarter last year
- Constant currency revenue rose 8.1% year on year, in line with the same quarter last year
- Market capitalization $24.78 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from STERIS’s Q3 earnings call
- Brett Fishbin (KeyBanc): asked about the rationale for acquiring Xodus Medical and its long-term fit. CEO Dan Carestio described it as providing a new clinical sales force in the operating room and cited high margin, high growth consumables as the attraction.
- Patrick Wood (UBS): inquired about utilization trends and margin leverage in AST as volumes recover. Carestio said the network has capacity and that incremental volumes should drive margin improvement, though new facility ramp-ups dilute margins in the near term.
- Mac Etoch (Stephens): asked about the impact of reshoring in Life Sciences. Carestio explained that customer plans are materializing into orders, with a notable $10 million order driving growth but clarified this was not expected to recur quarterly.
- Michael Polark (Wolfe Research): questioned the disconnect between healthcare consumables growth and muted AST volumes. Carestio attributed consumables growth to prior equipment placements and strong endoscopy-related demand, while AST volumes have been slower due to customer destocking.
- Jason Bednar (Piper Sandler): sought clarification on the revised AST guidance and procedure volume assumptions. Carestio said destocking has ended, and guidance assumes stable procedure growth at the lower end of historical trends, with easier year-over-year comparisons ahead.
Catalysts in upcoming quarters
For the coming quarters, our analyst team will be monitoring (1) the integration and early performance of Xodus Medical within STERIS’s core healthcare business, (2) the realization of cost savings from ongoing restructuring and facility realignment, and (3) sustained order strength in Life Sciences as onshoring and capital equipment demand evolve. We will also track whether procedure volumes and service adoption remain consistent, underpinning overall growth.
STERIS currently trades at $254.12, up from $247.91 just before the earnings. Is there an opportunity in the stock? See for yourself in our full research report (it’s free).
High-quality stocks for all market conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
